Anxiety and Depression Among Patients Newly Diagnosed with Lymphoma and Myeloma.

Although lymphoma and myeloma confer physical and psychological burden, data are limited regarding anxiety and depression symptoms in affected patients. We conducted a survey between 07/2021 and 09/2022 to characterize anxiety and depression in a cohort of adult patients, within six months of a lymphoma or myeloma diagnosis. Clinically significant anxiety and depression symptoms were defined as scores ≥8 on the corresponding subscales of the Hospital Anxiety and Depression Scale.

Understanding the Glycosylation Pathways Involved in the Biosynthesis of the Sulfated Glycan Ligands for Siglecs.

Carbohydrate sulfation plays a pivotal role in modulating the strength of Siglec-glycan interactions. Recently, new aspects of Siglec binding to sulfated cell surface carbohydrates have been discovered, but the class of glycan presenting these sulfated Siglec ligands has not been fully elucidated. In this study, the contribution of different classes of glycans to and Siglec ligands was investigated within cells expressing the carbohydrate sulfotransferase 1 (CHST1) or CHST2.

Fistulae Secondary to Vaginal Pessary Use for Pelvic Organ Prolapse: A Systematic Review.

Introduction And Hypothesis: Urogenital and rectovaginal fistulae are rare complications of pessary use for pelvic organ prolapse (POP). This systematic review investigates the prevalence of these complications in patients using pessary for POP, potential risk factors and approaches to their investigation and management.

Methods: All studies in English reporting urogenital or rectovaginal fistulae secondary to pessaries for POP were eligible for inclusion.

Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy.

Introduction: Endothelin A (ETA) receptor activation is a driver of proteinuria, kidney inflammation, and fibrosis in IgA nephropathy (IgAN). Atrasentan, a selective ETA receptor antagonist, has potential to reduce proteinuria and preserve kidney function in IgAN. ALIGN (NCT04573478) is a phase 3, randomized, double-blind, placebo-controlled clinical trial of atrasentan in patients with IgAN at high risk of kidney function loss.

Exploring a shared vision for success in permanent supportive housing: a community-partnered study in Colorado, USA.

In the United States and within Colorado, the number of persons experiencing homelessness has risen, with over 600,000 counted on a single night in 2023. Limited data integration across healthcare and social services hinders understanding of how permanent supportive housing (PSH) affects health outcomes. Our study in partnership with healthcare experts, housing providers, and a community advisory panel aimed to integrate data from health records, the justice system, and housing case manager notes to create a multidimensional measure of PSH success.